Literature DB >> 15781760

Curative surgery for recurrent nasopharyngeal carcinoma via the infratemporal fossa approach.

Jae Young Choi1, Won Sang Lee.   

Abstract

OBJECTIVE: To determine the proper indications (and thus define good candidates) for the infratemporal fossa approach (ITFA) in the treatment of recurrent nasopharyngeal carcinoma (NPC).
DESIGN: Retrospective analysis of 11 consecutive patients who had recurrent NPC after radiation therapy failure and were treated with curative surgery via the ITFA approach from July 1, 1993, to November 20, 1999. The mean follow-up was 32.5 months (range, 9-56 months).
SETTING: Academic tertiary referral center.
RESULTS: Patients who had a recurrent tumor confined to the Rosenmüller fossa (rT1; n = 3) or extending to the parapharynx (rT2; n = 3) maintained a clear surgical margin and were disease free. However, patients who had rT1 (n = 1) or rT2 (n = 1) tumors crossing the midline of the posterior nasopharyngeal wall had surgical margin involvement and their tumors recurred, and all patients with rT3 (n = 2) or rT4 (n = 1) tumors eventually died of the disease.
CONCLUSIONS: Resection of recurrent NPC via ITFA is useful for tumors located in the Rosenmüller fossa with or without parapharyngeal extension. However, tumors extending to the contralateral nasopharyngeal mucosa and tumors at an advanced stage are not suitable indications for ITFA.

Entities:  

Mesh:

Year:  2005        PMID: 15781760     DOI: 10.1001/archotol.131.3.213

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  2 in total

1.  Challenges in the management of nasopharyngeal carcinoma: a review.

Authors:  Baharudin Abdullah; Azila Alias; Shahid Hassan
Journal:  Malays J Med Sci       Date:  2009-10

2.  Outcomes of Recurrent Nasopharyngeal Carcinoma Patients Treated With Salvage Surgery: A Meta-Analysis.

Authors:  Yekai Feng; Zhimei Dai; Ruicheng Yan; Feng Li; Xiaosheng Zhong; Haoxin Ye; Caiqing Chen; Shaochong Fan; Cheng Qing; Yong Pan; Haiying Sun
Journal:  Front Oncol       Date:  2021-10-08       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.